Immunization of Rhesus monkeys with a SialylTn-mAb17-1A conjugate vaccine co-formulated with QS-21 induces a temporary systemic cytokine release and NK cytotoxicity against tumor cells

Cancer Immunology, Immunotherapy

Volumn 56, Issue 6, 2007, Pages 863-873

  Kircheis, Ralf ^a   Siegl, Petra ^a   Grunt, Susanne ^a   Halanek, Nicole ^a   Loibner, Hans ^a   Mudde, Geert C ^a   Nechansky, Andreas ^a  

^a Igeneon GmbH   (Austria)

Author keywords

Anti tumor cytotoxicity; Carbohydrate specific immune response; NK cell activation; QS 21; SialylTn; Type 1 cytokines

Indexed keywords

ALUMINUM HYDROXIDE; CANCER VACCINE; CARBOHYDRATE ANTIGEN; CARRIER PROTEIN; CYTOKINE; EDRECOLOMAB; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IGN 402; IMMUNOGLOBULIN G; INTERLEUKIN 1BETA; INTERLEUKIN 2; QS 21; SIALIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVATION; CELL KILLING; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; CYTOTOXICITY; DRUG CONJUGATION; DRUG FORMULATION; IMMUNE RESPONSE; IMMUNIZATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; TUMOR CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CANCER VACCINES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MACACA MULATTA; SAPONINS; VACCINES, CONJUGATE;

EID: 34248146542     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0231-x     Document Type: Article

References (42)

1. Antony PA, Restivo NP (2005) CD4 + CD25 + T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother 28:120-128
2. Clerici M, Shearer GM, Clerici E (1998) Cytokine dysregulation in invasive cervical carcinoma and other human neoplasias: time to consider the Th1/Th2 paradigm. J Natl Cancer Inst 90:261-263
3. Dranoff G, Jaffee E, Lazenby A et al (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539-3543
4. Fagerberg J, Frodin JE, Wigzell H, Mellstedt H (1993) Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy? Cancer Immunol Immunother 37:264-270
5. Fagerberg J, Ragnhammar P, Liljefors M, Hjelm AL, Mellstedt H, Frodin JE (1996) Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Cancer Immunol Immunother 42:81-87
6. Fearon ER, Pardoll DM, Itaya T et al (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397-403
7. Guo H, Qiao Z, Zhu L, Wang H, Su L, Lu Y, Cui Y, Jiang B, Zhu Q, Xu L (2004) Th1/Th2 cytokine profiles and their relationship to clinical features in patients following non-myeloablative allogeneic stem cell transplantation. Am J Hematol 75:78-83
8. Haurum JS, Holer IB, Arsequell G, Neisig A, Valencia G, Zeuthen J, Neefjes J, Elliott T (1999) Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J Exp Med 190:145-150
9. Hsueh EC, Essner R, Froshag LJ, Ye X, Morton DL (2001) Active immunotherapy by reinduction with a polyvalent allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma. Ann Surg Oncol 9:486-492
10. Itzkowitz SH, Yuan M, Montgomery CK, Kjeldsen T, Takahashi HK, Bigbee WL, Kim YS (1989) Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res 49:197-204
11. Itzkowitz SH, Bloom EJ, Kokal WA, Modin G, Hakomori S, Kim YS (1990) Sialosyl-Tn: a novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 66:1960-1966
12. Kammula US, White DE, Rosenberg SA (1998) Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 83:797-805
13. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA (1994) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458-6462
14. Kayaga J, Souberbielle BE, Sheikh N et al (1999) Antitumor activity against B16F10 melanoma with a GM-CSF-secreting allogeneic tumor cell vaccine. Gene Ther 6:1475-1481
15. Kircheis R, Küpcü Z, Wallner G, Wagner E (1998) Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFNγ, or combination IL-2 + IFNγ. Cytokines Cell Mol Ther 4:95-103
16. Kircheis R, Küpcü Z, Wallner G, Rössler V, Schweighoffer T, Wagner E (2000) Interleukin-2 gene-modified allogeneic melanoma cell vaccine can induce cross-protection against syngeneic tumors in mice. Cancer Gene Ther 7:870-878
17. Kircheis R, Vondru P, Nechansky A, Ohler R, Loibner H, Himmler G, Mudde GC (2005) SialylTn-mAb17-1A carbohydrate-protein conjugate vaccine: effect of coupling density and presentation of SialylTn. Bioconjug Chem 16(6):1519-1528
18. Kircheis R, Vondru P, Zinöcker I, Häring D, Nechansky A, Loibner H, Mudde GC (2006) Immunization of Rhesus monkeys with the conjugate vaccine IGN402 induces an IgG immune response against carbohydrate and protein antigens, and cancer cells. Vaccine 24:2349-2357
19. Knutson KL, Disis ML (2005) Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 5:365-371
20. Livingston PO, Wong GYC, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Helling F, Ritter G, Oettgen HF, Old LJ (1994) Improved survival in AJCC stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044
21. MacLean GD, Reddish MA, Koganty RR, Longenecker BM (1996) Antibodies against mucin-associated SialylTn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother 19:59-68
22. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (2000) Escape of human tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181-273
23. Nauts H, Fowler G, Bogatko F (1953) A review of the influence of bacterial infection and of bacterial products (Coley's toxin) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley's mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med Scand 144:S1-S103
24. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, Hemmi S, Hengartner H, Zinkernagel RM (2001) Roles of tumor location, second signals and cross priming in cytotoxic T-cell induction. Nature 411:1058-1064
25. Ortaldo JR, Herberman RB (1984) Heterogeneity of natural killer cells. Annu Rev Immunol 2:359-394
26. Ortaldo JR, Mason A, Overton R (1986) Lymphokine-activated killer cells: analysis of progenitors and effectors. J Exp Med 164:1193-1205
27. Panelli MC, White R, Foster M, Martin B, Wang E, Smith K, Marincola FM (2004) Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J Translat Med 2:17-31
28. Pardoll DM (1995) Paracrine cytokine adjuvants in cancer immunotherapy. Ann Rev Immunol 13:399-415
29. Ragupathi G, Koide F, Santhyan N, Kagan E, Spassova M, Bornmann W, Gregor P, Reis CA, Clausen H, Danishefsky SJ, Livingston PO (2003) A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancer. Cancer Immunol Immunother 52:608-616
30. Rayman P, Wesa AK, Richmond AL, Das T, Biswas K, Raval G, Storkus WJ, Tannenbaum C, Novick A, Bukowski R, Finke J (2004) Effect of renal cell carcinomas on the development of type-1 T-cell responses. Clin Cancer Res 10:6360S-6366S
31. Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirsche H, Pichlmayr R et al (1994) Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study group. Lancet 343:1172-1174
32. Rosenberg SA (1997) Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18:175-182
33. Schiller JH, Pugh M, Kirkwood JM, Karp D, Larson M, Borden E (1996) Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin Cancer Res 2:29-36
34. Settaf A, Salzberg M, Groiss F, Eller N, Schuster M, Himmler G, Kundi M, Eckert H, Loibner H (2004) A randomized placebo-controlled phase II study with the cancer vaccine IGN101 in patients with epithelial cancers. iSBTc 19th Annual Meeting, San Francisco, November, 4-7
35. Travers PJ, Arklie JL, Trowsdale J, Patillo RA, Bodmer WF (1982) Lack of expression of HLA-ABC antigens in choriocarcinoma and other human tumor cell lines. Natl Cancer Inst Monogr 60:175-180
36. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, DePlaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647
37. Watson SA, Michaeli D, Grimes S, Morris TM, Robinson G, Varro A, Justin TA, Hardcastle JD (1996) Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer. Cancer Res 56:880-885
38. Werdelin O, Meldal M, Jensen T (2002) Processing of glycans on glycoprotein and glycopeptide antigens in antigen-presenting cells. Proc Natl Acad Sci USA 99:9611-9613
39. Werther JL, Rivera-MacMurray S, Bruckner H, Tatematsu M, Itzkowitz SH (1994) Mucin-associated sialosyl-Tn antigen expression in gastric cancer correlates with an adverse outcome. Br J Cancer 69:613-616
40. Yamamura M, Modlin RL, Ohmen JD, Moy RL (1993) Local expression of anti-inflammatory cytokines in cancer. J Clin Invest 91:1005-1010
41. Zhang S, Walberg LA, Helling F, Ragupathi G, Adluri S, Lloyd KO, Livingston PO (1996) Augmenting the immunogenicity of synthetic MUC-1 vaccines in mice. Cancer Res 55:3364-3368
42. Zhang S, Zhang SH, Cordon-Cardo C, Reuter VE, Singgal AK, Lloyd KO, Livingston PO (1997) Selection of tumor antigens as targets for immune attack using immunohistochemistry. II. Blood group-related antigens. Int J Cancer 73:50-56